Aardvark Signs Deal to Commercialize two Oncology Drugs in Saudi Arabia
With a global market cap of $8B USD, Aardvark Pharma plans to take significant market share beginning in 2028 (May 2026).
Aardvark begins R&D for 10 drugs for its USA portfolio
Aardvark Pharma initiates research to register 10 oncology drugs with the US FDA by 2032 (October 2025).
Aardvark commits to register pain medication with Mexico Cofepris by 2027
With a market cap of $1B USD, Aardvark Pharma plans to achieve large market share over its commercialization (February 2025).
Aardvark signs contracts to distribute 16 drugs in UAE
Aardvark Pharma will initiate the registration process with MOHAP for 16 drugs from its portfolio and will receive commercial milestone payments (October 2023).
Aardvark signs distribution agreement in Saudi Arabia
Aardvark Pharma begins registration with Saudi FDA for 6 drugs from its portfolio and receives commercial milestones (September 2021).